Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B17a6f7f8974b5c6c0fd1749cfd336b8a> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B17a6f7f8974b5c6c0fd1749cfd336b8a NCIT_P378 "NCI" @default.
- B17a6f7f8974b5c6c0fd1749cfd336b8a type Axiom @default.
- B17a6f7f8974b5c6c0fd1749cfd336b8a annotatedProperty IAO_0000115 @default.
- B17a6f7f8974b5c6c0fd1749cfd336b8a annotatedSource NCIT_C97272 @default.
- B17a6f7f8974b5c6c0fd1749cfd336b8a annotatedTarget "The dihydrochloride salt form of quizartinib, an orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases." @default.